3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Phase 1/2
1
Status
Completed
9
Recruiting
8
Not yet recruiting
3
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
387
Breast Neoplasms
368
Colorectal Neoplasms
242
Stomach Neoplasms
221
Carcinoma, Hepatocellular
155
Lung Neoplasms
125
Neoplasms
122
Pancreatic Neoplasms
112
Prostatic Neoplasms
101
Rectal Neoplasms
98
Neoplasm Metastasis
98
Recurrence
94
Ovarian Neoplasms
92
Nasopharyngeal Carcinoma
89
Esophageal Neoplasms
84
Esophageal Squamous Cell Carcinoma
83
Lymphoma, Large B-Cell, Diffuse
80
Melanoma
78
Lymphoma
72
Small Cell Lung Carcinoma
71
Sarcoma
71
Leukemia, Myeloid, Acute
71
Uterine Cervical Neoplasms
70
Brain Neoplasms
70
Squamous Cell Carcinoma of Head and Neck
67
Multiple Myeloma
67
Head and Neck Neoplasms
67
Carcinoma, Renal Cell
65
Triple Negative Breast Neoplasms
63
Colonic Neoplasms
55
Interventions
liposomal doxorubicin
1
Dexamethasone
1
Calcium Dobesilate
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Unknown
×
Leukemia, Plasma Cell
×
Clear all
NCT01328236
2011-09-22
Bortezomib
Clinical Service, China
Phase 2
Unknown
20 enrolled